Andrew Marr assesses the impact of the EMA announcement on Medicinal Product Information

Andrew Marr assesses the impact of the of the EMA announcement of 1 July 2011 on the mandatory provision of medicinal product information (EVMPD) by 2 July 2012.

This article was published in the August 2011 issue of Scrip Regulatory Affairs (see www.scripregulatoryaffairs.com).

Click here for Journal Article